Enliven Therapeutics (NASDAQ:ELVN) Shares Down 6.5% Following Insider Selling

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report)'s stock price dropped 6.5% on Thursday after an insider sold shares in the company. The company traded as low as $19.36 and last traded at $18.8590. Approximately 54,409 shares traded hands during mid-day trading, a decline of 87% from the average daily volume of 430,945 shares. The stock had previously closed at $20.17.Get Enliven Therapeutics alerts:Specifically, COO Anish Patel sold 6,663 shares of the business's stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $21.02, for a total value of $140,056.26. Following the sale, the chief operating officer directly owned 263,311 shares in the company, valued at approximately $5,534,797.22. The trade was a 2.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Wall Street Analyst Weigh InSeveral research firms have recently issued reports on ELVN. Weiss Ratings reissued a "sell (d-)" rating on shares of Enliven Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Enliven Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, November 15th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $41.20.Get Our Latest Stock Analysis on Enliven TherapeuticsEnliven Therapeutics Trading Down 6.1%The stock has a fifty day simple moving average of $20.86 and a two-hundred day simple moving average of $20.43. The firm has a market cap of $1.12 billion, a PE ratio of -10.17 and a beta of 0.35. Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.32) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.11. As a group, sell-side analysts predict that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year. Institutional Inflows and OutflowsHedge funds have recently made changes to their positions in the company. Vestal Point Capital LP raised its position in shares of Enliven Therapeutics by 364.0% in the third quarter. Vestal Point Capital LP now owns 1,160,000 shares of the company's stock worth $23,745,000 after buying an additional 910,000 shares in the last quarter. TCG Crossover Management LLC bought a new position in Enliven Therapeutics in the 2nd quarter worth about $9,990,000. Duquesne Family Office LLC raised its holdings in shares of Enliven Therapeutics by 104.6% in the 3rd quarter. Duquesne Family Office LLC now owns 947,405 shares of the company's stock valued at $19,393,000 after acquiring an additional 484,405 shares in the last quarter. Candriam S.C.A. bought a new stake in shares of Enliven Therapeutics during the 2nd quarter valued at about $8,358,000. Finally, Franklin Resources Inc. grew its holdings in shares of Enliven Therapeutics by 2,029.3% during the second quarter. Franklin Resources Inc. now owns 430,240 shares of the company's stock worth $8,631,000 after purchasing an additional 410,034 shares in the last quarter. 95.08% of the stock is currently owned by hedge funds and other institutional investors. About Enliven Therapeutics (Get Free Report)Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.Featured StoriesFive stocks we like better than Enliven TherapeuticsWhat Are Dividends? Buy the Best Dividend StocksTesla Bulls See $500 Ahead—But Bears Warn of a Painful ReversalTechnology Stocks Explained: Here's What to Know About TechMissed NVIDIA? Braze Might Be the Next AI Stock BreakoutREIT Stocks - Best REIT Stocks to Add to Your Portfolio TodayWalmart’s NASDAQ Switch Could Change Everything for WMT StockThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Enliven Therapeutics Right Now?Before you consider Enliven Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.While Enliven Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here